SOL SHERRY; WILLIAM R. BELL; F. H. DUCKERT; ANTHONY P. FLETCHER; VICTOR GUREWICH; DAVID M. LONG; VICTOR J. MARDER; HAROLD ROBERTS; EDWIN W. SALZMAN; ARTHUR SASAHARA; MARC VERSTRAETE
This content is PDF only. Please click on the PDF icon to access.
For over three decades, the primary method of therapy used by almost all physicians for the management of acute deep-vein thrombosis and pulmonary embolism has been anticoagulation. This form of therapy has become so ingrained in medical practice that physicians, although still concerned over the bleeding risk associated with the use of anticoagulants, nevertheless seem secure in the belief that they are providing optimal, if not ideal, therapy for these disorders. With the advent of thrombolytic therapy (the thrombolytic agents considered at this conference were urokinase and streptokinase), this is no longer true for many cases. Anticoagulation for the management
SHERRY S, BELL WR, DUCKERT FH, FLETCHER AP, GUREWICH V, LONG DM, et al. Thrombolytic Therapy in Thrombosis: A National Institutes of Health Consensus Development Conference. Ann Intern Med. ;93:141–144. doi: 10.7326/0003-4819-93-1-141
Download citation file:
Published: Ann Intern Med. 1980;93(1_Part_1):141-144.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use